ArticleActa diabetologica2026
In vitro and in silico analysis of three variants associated with type 2 diabetes.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCommon regulatory and coding variants may influence type 2 diabetes (T2D) risk by altering gene regulation or protein function. Identifying these variants and their associations with disease risk may inform disease control strategies. This study prioritized candidate variants by integrating two-group comparative genotyping with in-silico structural and dynamic analyses.
methodsThree prioritized variants (two missense, one TF-binding-site) were genotyped in 101 T2D cases and 100 controls from the Azeri population of Iran. Variant calls were validated by Sanger sequencing. Structural modelling, ligand docking, and 100-nanosecond molecular dynamics simulations were performed to assess molecular consequences.
resultsThe TF-binding-site variant in PPP2R3A (rs184442184) was significantly associated with T2D (allelic OR ≈ 1.71, p = 0.014; TT OR ≈ 2.92, p = 0.020) and is located at a RegulomeDB 2a site overlapping EGR1/SP motifs. SLC39A11 (ZIP11) rs61736066 (A allele) was enriched in cases (allelic OR ≈ 1.87, p = 0.002; AA OR ≈ 3.49, p = 0.005), and the variant model demonstrated increased RMSD/RMSF, helix displacement, and modest destabilization. The TPCN2 missense variant exhibited only subtle in-silico effects and no genetic association.
conclusionThese findings highlight PPP2R3A rs184442184 and SLC39A11 rs61736066 as promising T2D candidate variants, supported by concordant genetic signals and mechanistic in-silico effects. The TPCN2 substitution demonstrated only mild structural changes and no association in this study. Overall, these results provide testable biological hypotheses that require validation through larger replication studies and targeted functional assays.
Indexed as
Identifiers
42089960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.